Royal DSM N.V. and Avecia announced today that DSM intends to acquire NeoResins, the coating resins business of Avecia. It is anticipated that the closing will take place in the first quarter of 2005.
DSM Anti-Infectives, the world’s largest producer of penicillin and antibiotic products (including amoxicillins and cephalosporins), has this morning announced a drastic package of measures, in accordance with the announcement made during the presentation of DSM’s third-quarter results.
Royal DSM N.V. repurchased all of the outstanding 37,500,000 cumulative preference shares C at the original issue price of EUR 3.03 per share, at the contractually agreed dividend reset date (28 November 2004).
Today, Royal DSM N.V., headquartered in Heerlen, The Netherlands, confirmed that it is engaged in discussions with North China Pharmaceutical Group Corporation (“NCPC”) of Shijiazhuang, Hebei Province, People’s Republic of China, regarding a strategic partnership via a.o. participation in the equity ownership of North China Pharmaceutical Company, Ltd. (“NCPC Ltd.”), a company which is listed on the Shanghai stock exchange.
The Supervisory Board of DSM will propose to the Annual General Meeting of Shareholders on April 6, 2005 to appoint to the Managing Board of DSM with effect from the same date.
DSM posted an operating profit of EUR 133 million in Q3 2004. This is EUR 107 million higher than in Q3 2003 and at the level of Q2 2004. The profit on ordinary activities after taxation amounted to EUR 98 million, up EUR 78 million from Q3 2003 and in line with Q2 2004.
Bernard van Schaik (53), currently Business Group Director of DSM Pharmaceutical Products, has been appointed Director of Corporate Communications in Heerlen (NL) with effect from 1 December of this year.
Royal DSM N.V. has recently changed its legal structure. Instead of a company operating under the Large Company Regime applicable in the Netherlands it is now an ordinary public limited company.
DSM, the Netherlands based Life Sciences and Performance Materials company, will be hosting its annual Chemical Analysts Conference today and tomorrow at Castle Vaalsbroek (in the Netherlands). This conference for financial analysts will be webcast via the DSM website.
DSM Venturing today announced that it has invested in Sciona Inc., based in Connecticut (USA). Sciona is a provider of personalized, science-based actionable healthcare advice.
The Dow Jones Sustainability World Index has today named DSM NV, the Netherlands based Life Sciences and Performance Materials company, as the worldwide Sustainability Leader in the Chemical Industry.
Dutch sculler Dirk Lippits will change the ‘look’ of Olympic rowing on Saturday by competing in a specially designed and futuristic looking helmet, designed to help keep his head temperature as low as possible.
As of 1 July 2004, Ton Trommelen (54) is the Chief Purchasing Officer (CPO) at DSM. Trommelen, who has joined DSM from Philips Semiconductors, will report directly to the Managing Board.
In the second quarter of 2004 DSM posted an operating profit of EUR 133 million. Operating profit was EUR 48 million higher than in the second quarter of 2003 and EUR 23 million higher than the Q1 2004 level. Net profit amounted to EUR 97 million, up EUR 29 million from the second quarter of 2003.
Today DSM Melamine and China National Offshore Oil Corp. Chemical Ltd. (CNOOCC) signed a letter of intent to study jointly the feasibility of building a new 120 kt melamine plant on Hainan Island, China.
As one of the first companies listed on the Euronext AEX index, DSM is introducing a whistleblower policy. The Managing Board of Directors has recently approved the policy, which offers protection to employees who report abuses within the company.
DSM Dyneema, producer of the world’s strongest fiber, today announced that it has started building a production line for Dyneema® Purity, a high performance fiber for use in medical applications, such as strong orthopedic sutures and other surgical implants.
DSM Dyneema, the world’s largest producer of high-performance polyethylene fiber, officially opened its first yarn production line today at the U.S. Dyneema facility in Greenville, North Carolina.
DSM Anti-Infectives, the world’s largest producer of antibiotics, will expand its existing ZOR-f plant in Delft for the production of 7-ADCA. 7-ADCA is an advanced intermediate for the production of cephalosporins, an important group of antibiotics.
In the first quarter of 2004 DSM posted an operating profit of EUR 110 million, which is EUR 19 million higher than in the first quarter of 2003. The profit on ordinary activities after taxation was EUR 74 million. Net profit was EUR 79 million, up EUR 6 million (8%) from Q1 2003.
DSM Engineering Plastics has announced an expansion of its Akulon PA6 capacity at its polyamide plant in Emmen, the Netherlands. The plant will be completed by mid 2005.
When presenting this report, Peter Elverding, Chairman of DSM’s Managing Board, also made public the company’s performance in the areas of emission reductions and safety.
PeptoPro®Sports, the recovery drink developed by DSM has been officially certified as doping-free by the DoCoLab at the University of Ghent, Belgium. NUTRIM is to start new scientific tests on 1 March to learn more on the efficacy of the drink.
Today DSM announced the initial results of its “Copernicus” project, which is aimed at boosting the efficiency and effectiveness of the company’s manufacturing activities at the Chemelot site in Geleen (Netherlands).
DSM Nutritional Products, the former Roche division Vitamins & Fine Chemicals, which was acquired by DSM on 30 September 2003, announces further steps in its integration and transformation process.
